Non-Fucosylated Anti-Human HER2 (v5019) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1717ZP) Datasheet

ERBB2

erb-b2 receptor tyrosine kinase 2

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.

NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

v5019

Human

Human

Non-fucosylated v5019 (v5019-afuco) at maximum cell lysis about 1.5-1.7 times higher than Herceptin / 1 + HER2-expressing breast cancer cells are shown to induce ADCC.

HER2-positive breast cancer; metastatic breast cancer

v7187